Bone Biologics Corp

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

For the Six Months ended June 30, 2025

(unaudited)(1)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2024	492,417	$492	$88,504,543	$(85,021,378)	$3,483,657
Fair value of vested stock options	-	-	50,605	-	50,605
Options issued to settle accrued bonus	-	-	46,183	-	46,183
Issuance of common shares from ATM, net of costs of $13,029	52,843	53	347,496	-	347,549
Net Loss	-	-	-	(1,017,092)	(1,017,092)
Balance at March 31, 2025	545,260	545	88,948,827	(86,038,470)	2,910,902
Fair value of vested stock options	-	-	72,899	-	72,899
Proceeds from sale of common stock and warrants in public offering, net of offering costs of $647,208	793,750	794	4,351,998	-	4,352,792
Exercise of pre-funded warrants	346,250	346	(346)	-	-
Net Loss	-	-	-	(740,519)	(740,519)
Balance at June 30, 2025	1,685,260	$1,685	$93,373,378	$(86,778,989)	$6,596,074

(1) Adjusted to reflect the reverse stock split as described in Note 1.

Consolidated Statement of Stockholders’ Equity

For the Six Months ended June 30, 2024

(unaudited)(1)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2023	89,127	$89	$83,815,230	$(80,908,958)	$2,906,361
Fair value of vested stock options	-	-	52,681	-	52,681
Options issued to settle accrued bonus	-	-	77,400	-	77,400
Proceeds from sale of common stock in public offering, net of offering costs of $490,227	19,833	20	1,504,319	-	1,504,339
Exercise of pre-funded warrants	60,542	60	77	-	137
Net Loss	-	-	-	(865,970)	(865,970)
Balance at March 31, 2024	169,502	169	85,449,707	(81,774,928)	3,674,948
Fair value of vested stock options	-	-	17,443	-	17,443
Exercise of pre-funded warrants	49,833	50	249	-	299
Net Loss	-	-	-	(783,733)	(783,733)
Balance at June 30, 2024	219,335	$219	$85,467,399	$(82,558,661)	$2,908,957

(1) Adjusted to reflect the reverse stock split as described in Note 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.